MedTrace Logo

Leucoaraiosis and Multimodal MRI With Fingerprinting Technique

NCT06181981 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-12-26

No results posted yet for this study

Summary

Leukoaraiosis (LA) corresponds to an alteration of the encephalic white matter, linked to chronic hypoxia. Its pathophysiology, which has been partially elucidated, is underpinned by chronic changes in the walls of small-caliber perforating arteries, leading to chronic hypoperfusion of the white matter, associated with dysfunction of the blood-brain barrier. In affected areas, this process leads to myelin rarefaction, axonal loss, perivascular alterations and the appearance of cavitation zones. Its existence is mainly linked to the presence of vascular risk factors, most notably arterial hypertension.

MR fingerprinting is an innovative Magnetic resonance Imaging (MRI) technique allowing to obtain a multiparametric MRI sequence in a non-invasively way and in a single acquisition, generating not only multiple contrasts, but also absolute longitudinal relaxation time (T1) and transverse relaxation time (T2) mappings (T1 and T2 mapping). However, the prognostic role of these T2 values, in terms of ischemic, hemorrhagic and cognitive risk, has never been studied. The objective of this study is to study and compare changes in T1 and T2 values of White Matter Hyperintensities (WMH) and Normal Appearing White Matter (NAWM) in subjects with LA.

Conditions

  • Leukoaraiosis
  • Magnetic Resonance Imaging

Interventions

DIAGNOSTIC_TEST

MRI fingerprinting

This method allows to get quantitative magnetic resonance imaging for the simultaneous measurement of multiple tissue properties in a single, time-efficient acquisition

Sponsors & Collaborators

  • University Hospital, Lille

    collaborator OTHER

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Sébastien VERCLYTTE, MD · Groupement des Hopitaux de l'institut catholique de Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-14
Primary Completion
2024-11-30
Completion
2025-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06181981 on ClinicalTrials.gov